30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Olema Pharmaceuticals Inc (OLMA)

Track

Recent insider trading activity at Olema Pharmaceuticals Inc. primarily consists of proposed and actual sales by former officer Shane William Charles Kovacs and Chief Legal Officer Shawnte Mitchell. The most recent transactions occurred on March 16, 2026, involving significant proposed sales by Kovacs. Mitchell also engaged in both proposed sales and actual sales around early March 2026.
Stock chart
Ticker: OLMA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Kovacs Shane William Charles
Former Officer
2 sales — total 1,676,897 USD
Proposed sale 16 Mar 2026
Value US$1,703,118.50 | Price 271.98 | Shares 50,738
Proposed sale 16 Mar 2026
Value US$2,130,478.19 | Price 404.19 | Shares 87,638
Proposed sale 11 Mar 2026
Value US$181,906.13 | Price 410.57 | Shares 29,718
Proposed sale 10 Mar 2026
Value US$904,566.21 | Price 17.00 | Shares 53,206
Proposed sale 9 Mar 2026
Value US$3,254,933.05 | Price 13.45 | Shares 241,999
Sale 4 Mar 2026
Value US$5,752.77 | Price 24.69 | Shares 233
Sale 4 Mar 2026
Value US$600,599.75 | Price 24.25 | Shares 24,767
Proposed sale 4 Mar 2026
Value US$598,500.00 | Price 23.94 | Shares 25,000
Proposed sale 4 Mar 2026
Value US$488,653.67 | Price 24.43 | Shares 20,000
Sale 3 Mar 2026
Value US$345,150.00 | Price 23.01 | Shares 15,000
Proposed sale 3 Mar 2026
Value US$345,152.83 | Price 23.01 | Shares 15,000
Proposed sale 27 Feb 2026
Value US$163,026.25 | Price 25.00 | Shares 6,521
Proposed sale 24 Feb 2026
Value US$500,002.00 | Price 25.00 | Shares 20,000
Proposed sale 23 Feb 2026
Value US$243,000.46 | Price 24.30 | Shares 10,000
Proposed sale 23 Feb 2026
Value US$480,007.00 | Price 24.00 | Shares 20,000
Proposed sale 12 Feb 2026
Value US$238,498.19 | Price 23.85 | Shares 10,000
Sale 20 Jan 2026
Value US$268,800.00 | Price 26.88 | Shares 10,000
Proposed sale 20 Jan 2026
Value US$268,762.74 | Price 26.88 | Shares 10,000
Proposed sale 15 Jan 2026
Value US$2,873,214.99 | Price 28.73 | Shares 100,000
Sale 15 Jan 2026
Value US$2,873,000.00 | Price 28.73 | Shares 100,000
Sale 14 Jan 2026
Value US$101,599.68 | Price 29.12 | Shares 3,489
Proposed sale 14 Jan 2026
Value US$101,603.33 | Price 29.12 | Shares 3,489
Proposed sale 14 Jan 2026
Value US$1,443,631.44 | Price 28.87 | Shares 50,000
Sale 14 Jan 2026
Value US$1,014,736.97 | Price 28.99 | Shares 35,003
Sale 14 Jan 2026
Value US$428,914.20 | Price 28.60 | Shares 14,997
Sale 13 Jan 2026
Value US$107,054.22 | Price 28.01 | Shares 3,822
Proposed sale 13 Jan 2026
Value US$107,069.20 | Price 28.01 | Shares 3,822
Sale 13 Jan 2026
Value US$5,698.00 | Price 28.49 | Shares 200
Sale 13 Jan 2026
Value US$1,374,480.00 | Price 27.60 | Shares 49,800
Proposed sale 13 Jan 2026
Value US$1,380,112.65 | Price 27.60 | Shares 50,000
Sale 12 Jan 2026
Value US$283,400.00 | Price 28.34 | Shares 10,000
Proposed sale 12 Jan 2026
Value US$283,362.96 | Price 28.34 | Shares 10,000
Proposed sale 23 Dec 2025
Value US$2,752,165.18 | Price 27.66 | Shares 99,509
Sale 23 Dec 2025
Value US$2,752,418.94 | Price 27.66 | Shares 99,509
Sale 22 Dec 2025
Value US$82,194.93 | Price 28.53 | Shares 2,881
Proposed sale 22 Dec 2025
Value US$82,182.00 | Price 28.53 | Shares 2,881
Sale 22 Dec 2025
Value US$2,804,000.00 | Price 28.04 | Shares 100,000
Proposed sale 22 Dec 2025
Value US$2,804,038.90 | Price 28.04 | Shares 100,000
Sale 19 Dec 2025
Value US$189,783.94 | Price 31.39 | Shares 6,046
Sale 19 Dec 2025
Value US$1,329,361.60 | Price 30.40 | Shares 43,729
Planned sale 19 Dec 2025
Value US$34,398.00 | Price 28.08 | Shares 1,225
Proposed sale 19 Dec 2025
Value US$1,553,447.42 | Price 30.46 | Shares 51,000
Sale 19 Dec 2025
Value US$373,804.53 | Price 28.93 | Shares 12,921
Sale 19 Dec 2025
Value US$1,599,924.37 | Price 28.03 | Shares 57,079
Proposed sale 19 Dec 2025
Value US$1,973,560.69 | Price 28.19 | Shares 70,000
Sale 19 Dec 2025
Value US$1,275,283.20 | Price 30.48 | Shares 41,840
Sale 19 Dec 2025
Value US$5,735,693.76 | Price 29.71 | Shares 193,056
Sale 19 Dec 2025
Value US$862,132.32 | Price 28.83 | Shares 29,904
Proposed sale 19 Dec 2025
Value US$7,873,501.64 | Price 29.73 | Shares 264,800
Proposed sale 18 Sep 2025
Value US$108,977.56 | Price 8.33 | Shares 13,086
Sale 18 Sep 2025
Value US$25,675.52 | Price 8.32 | Shares 3,086
Sale 18 Sep 2025
Value US$83,300.00 | Price 8.33 | Shares 10,000
Sale 16 Sep 2025
Value US$15,465.12 | Price 8.08 | Shares 1,914
Sale 16 Sep 2025
Value US$80,400.00 | Price 8.04 | Shares 10,000
Proposed sale 16 Sep 2025
Value US$95,826.88 | Price 8.04 | Shares 11,914
Buy 8 Jan 2025
Value US$1,727,370.00 | Price 5.76 | Shares 300,000
Sale 17 Dec 2024
Value US$4,730,136.75 | Price 6.75 | Shares 700,761
Proposed sale 13 Dec 2024
Value US$4,730,136.75 | Price 6.75 | Shares 700,761
Proposed sale 11 Dec 2024
Value US$70,634.80 | Price 8.68 | Shares 8,137
Sale 11 Dec 2024
Value US$1,680.81 | Price 9.39 | Shares 179
Sale 11 Dec 2024
Value US$68,916.28 | Price 8.66 | Shares 7,958
Proposed sale 11 Dec 2024
Value US$159,345.02 | Price 8.68 | Shares 18,356
Sale 11 Dec 2024
Value US$3,812.34 | Price 9.39 | Shares 406
Sale 11 Dec 2024
Value US$155,447.00 | Price 8.66 | Shares 17,950
Proposed sale 11 Dec 2024
Value US$118,180.04 | Price 8.68 | Shares 13,614
Sale 11 Dec 2024
Value US$2,817.00 | Price 9.39 | Shares 300
Sale 11 Dec 2024
Value US$115,299.24 | Price 8.66 | Shares 13,314
Proposed sale 11 Dec 2024
Value US$126,062.11 | Price 8.68 | Shares 14,522
Sale 11 Dec 2024
Value US$3,004.80 | Price 9.39 | Shares 320
Sale 11 Dec 2024
Value US$122,989.32 | Price 8.66 | Shares 14,202
Proposed sale 11 Dec 2024
Value US$496,322.01 | Price 8.68 | Shares 57,174
Sale 11 Dec 2024
Value US$11,897.13 | Price 9.39 | Shares 1,267
Sale 11 Dec 2024
Value US$484,154.62 | Price 8.66 | Shares 55,907
Sale 10 Dec 2024
Value US$77,358.72 | Price 9.37 | Shares 8,256
Sale 10 Dec 2024
Value US$157,444.11 | Price 9.37 | Shares 16,803
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-16 2026-03-16 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
50,738
271.98
US$1,703,119 		50,738 271.98 US$1,703,119
2026-03-16 2026-03-16 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
87,638
404.19
US$2,130,478 		87,638 404.19 US$2,130,478
2026-03-11 2026-03-11 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
29,718
410.57
US$181,906 		29,718 410.57 US$181,906
2026-03-10 2026-03-10 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
53,206
17.00
US$904,566 		53,206 17.00 US$904,566
2026-03-09 2026-03-09 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
241,999
13.45
US$3,254,933 		241,999 13.45 US$3,254,933
2026-03-05 2026-03-04 S Sale
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
233 -100.0%
24.69
US$5,753 		233 -100.0% 24.69 US$5,753
2026-03-05 2026-03-04 S Sale
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
24,767 -99.1%
24.25
US$600,600 		24,767 -99.1% 24.25 US$600,600
2026-03-04 2026-03-04 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
24.43
US$488,654 		20,000 24.43 US$488,654
2026-03-04 2026-03-04 PrS Proposed sale
Mitchell Shawnte

Officer

Officer
25,000
23.94
US$598,500 		25,000 23.94 US$598,500
2026-03-05 2026-03-03 S Sale
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
15,000 -100.0%
23.01
US$345,150 		15,000 -100.0% 23.01 US$345,150
2026-03-03 2026-03-03 PrS Proposed sale
Mitchell Shawnte

Officer

Officer
15,000
23.01
US$345,153 		15,000 23.01 US$345,153
2026-02-27 2026-02-27 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
6,521
25.00
US$163,026 		6,521 25.00 US$163,026
2026-02-24 2026-02-24 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
25.00
US$500,002 		20,000 25.00 US$500,002
2026-02-23 2026-02-23 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
10,000
24.30
US$243,000 		10,000 24.30 US$243,000
2026-02-23 2026-02-23 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
24.00
US$480,007 		20,000 24.00 US$480,007
2026-02-12 2026-02-12 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
10,000
23.85
US$238,498 		10,000 23.85 US$238,498
2026-01-21 2026-01-20 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.4%
26.88
US$268,800 		10,000 -1.4% 26.88 US$268,800
2026-01-20 2026-01-20 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
10,000
26.88
US$268,763 		10,000 26.88 US$268,763
2026-01-15 2026-01-15 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
100,000
28.73
US$2,873,215 		100,000 28.73 US$2,873,215
2026-01-15 2026-01-15 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
100,000 -41.7%
28.73
US$2,873,000 		100,000 -41.7% 28.73 US$2,873,000
2026-01-16 2026-01-14 S Sale
2.9
Harmon Cyrus
Non-Executive Director
3,489 -0.5%
29.12
US$101,600 		3,489 -0.5% 29.12 US$101,600
2026-01-14 2026-01-14 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
3,489
29.12
US$101,603 		3,489 29.12 US$101,603
2026-01-14 2026-01-14 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
50,000
28.87
US$1,443,631 		50,000 28.87 US$1,443,631
2026-01-14 2026-01-14 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
35,003 -6.1%
28.99
US$1,014,737 		35,003 -6.1% 28.99 US$1,014,737
2026-01-14 2026-01-14 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
14,997 -2.5%
28.60
US$428,914 		14,997 -2.5% 28.60 US$428,914
2026-01-15 2026-01-13 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
3,822 -1.6%
28.01
US$107,054 		3,822 -1.6% 28.01 US$107,054
2026-01-14 2026-01-13 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
200 -0.0%
28.49
US$5,698 		200 -0.0% 28.49 US$5,698
2026-01-14 2026-01-13 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
49,800 -8.4%
27.60
US$1,374,480 		49,800 -8.4% 27.60 US$1,374,480
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
3,822
28.01
US$107,069 		3,822 28.01 US$107,069
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
50,000
27.60
US$1,380,113 		50,000 27.60 US$1,380,113
2026-01-14 2026-01-12 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
10,000 -6.5%
28.34
US$283,400 		10,000 -6.5% 28.34 US$283,400
2026-01-12 2026-01-12 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
10,000
28.34
US$283,363 		10,000 28.34 US$283,363
2025-12-23 2025-12-23 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
99,509
27.66
US$2,752,165 		99,509 27.66 US$2,752,165
2025-12-23 2025-12-23 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
99,509 -95.7%
27.66
US$2,752,419 		99,509 -95.7% 27.66 US$2,752,419
2025-12-29 2025-12-22 S Sale
2.9
Harmon Cyrus
Non-Executive Director
2,881 -0.4%
28.53
US$82,195 		2,881 -0.4% 28.53 US$82,195
2025-12-23 2025-12-22 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
100,000 -64.9%
28.04
US$2,804,000 		100,000 -64.9% 28.04 US$2,804,000
2025-12-22 2025-12-22 PrS Proposed sale
2.9
Harmon Cyrus

Officer

Officer
2,881
28.53
US$82,182 		2,881 28.53 US$82,182
2025-12-22 2025-12-22 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
100,000
28.04
US$2,804,039 		100,000 28.04 US$2,804,039
2025-12-23 2025-12-19 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
6,046 -1.1%
31.39
US$189,784 		6,046 -1.1% 31.39 US$189,784
2025-12-23 2025-12-19 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
43,729 -7.3%
30.40
US$1,329,362 		43,729 -7.3% 30.40 US$1,329,362
2025-12-23 2025-12-19 PlS Planned sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
1,225 -0.2%
28.08
US$34,398 		1,225 -0.2% 28.08 US$34,398
2025-12-23 2025-12-19 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
12,921 -11.1%
28.93
US$373,805 		12,921 -11.1% 28.93 US$373,805
2025-12-23 2025-12-19 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
57,079 -32.8%
28.03
US$1,599,924 		57,079 -32.8% 28.03 US$1,599,924
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
41,840 -100.0%
30.48
US$1,275,283 		41,840 -100.0% 30.48 US$1,275,283
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
193,056 -82.2%
29.71
US$5,735,694 		193,056 -82.2% 29.71 US$5,735,694
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
29,904 -11.3%
28.83
US$862,132 		29,904 -11.3% 28.83 US$862,132
2025-12-19 2025-12-19 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
51,000
30.46
US$1,553,447 		51,000 30.46 US$1,553,447
2025-12-19 2025-12-19 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
70,000
28.19
US$1,973,561 		70,000 28.19 US$1,973,561
2025-12-19 2025-12-19 PrS Proposed sale
3.9
CLARK IAN T

Director

Non-Executive Director
264,800
29.73
US$7,873,502 		264,800 29.73 US$7,873,502
2025-09-18 2025-09-18 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
13,086
8.33
US$108,978 		13,086 8.33 US$108,978
2025-09-18 2025-09-18 S Sale
2.9
Harmon Cyrus
Non-Executive Director
3,086 -2.6%
8.32
US$25,676 		3,086 -2.6% 8.32 US$25,676
2025-09-18 2025-09-18 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.3%
8.33
US$83,300 		10,000 -1.3% 8.33 US$83,300
2025-09-18 2025-09-16 S Sale
2.9
Harmon Cyrus
Non-Executive Director
1,914 -1.6%
8.08
US$15,465 		1,914 -1.6% 8.08 US$15,465
2025-09-18 2025-09-16 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.3%
8.04
US$80,400 		10,000 -1.3% 8.04 US$80,400
2025-09-16 2025-09-16 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
11,914
8.04
US$95,827 		11,914 8.04 US$95,827
2025-01-13 2025-01-08 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
300,000 +4.0%
5.76
US$1,727,370 		300,000 +4.0% 5.76 US$1,727,370
2024-12-17 2024-12-17 S Sale
3.0
Graham G. Walmsley
Non-Executive Director
700,761 -100.0%
6.75
US$4,730,137 		700,761 -100.0% 6.75 US$4,730,137
2024-12-13 2024-12-13 PrS Proposed sale
Logos Opportunities Fund I LP

Affiliate
700,761
6.75
US$4,730,137 		700,761 6.75 US$4,730,137
2024-12-11 2024-12-11 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
8,137
8.68
US$70,635 		8,137 8.68 US$70,635
2024-12-11 2024-12-11 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
18,356
8.68
US$159,345 		18,356 8.68 US$159,345
2024-12-11 2024-12-11 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
13,614
8.68
US$118,180 		13,614 8.68 US$118,180
2024-12-11 2024-12-11 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
14,522
8.68
US$126,062 		14,522 8.68 US$126,062
2024-12-11 2024-12-11 PrS Proposed sale
3.8
Bohen Sean

Officer; Director

Executive Director
57,174
8.68
US$496,322 		57,174 8.68 US$496,322
2024-12-11 2024-12-11 S Sale
2.9
Harmon Cyrus
Non-Executive Director
179 -0.0%
9.39
US$1,681 		179 -0.0% 9.39 US$1,681
2024-12-11 2024-12-11 S Sale
2.9
Harmon Cyrus
Non-Executive Director
7,958 -1.0%
8.66
US$68,916 		7,958 -1.0% 8.66 US$68,916
2024-12-11 2024-12-11 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
406 -0.1%
9.39
US$3,812 		406 -0.1% 9.39 US$3,812
2024-12-11 2024-12-11 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
17,950 -3.2%
8.66
US$155,447 		17,950 -3.2% 8.66 US$155,447
2024-12-11 2024-12-11 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
300 -0.1%
9.39
US$2,817 		300 -0.1% 9.39 US$2,817
2024-12-11 2024-12-11 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
13,314 -2.2%
8.66
US$115,299 		13,314 -2.2% 8.66 US$115,299
2024-12-11 2024-12-11 S Sale
3.8
Bohen Sean

PRESIDENT AND CEO

Executive Director
1,267 -0.5%
9.39
US$11,897 		1,267 -0.5% 9.39 US$11,897
2024-12-11 2024-12-11 S Sale
3.8
Bohen Sean

PRESIDENT AND CEO

Executive Director
55,907 -18.7%
8.66
US$484,155 		55,907 -18.7% 8.66 US$484,155
2024-12-11 2024-12-11 S Sale
4.0
Zojwalla Naseem

CHIEF MEDICAL OFFICER

Officer
320 -0.3%
9.39
US$3,005 		320 -0.3% 9.39 US$3,005
2024-12-11 2024-12-11 S Sale
4.0
Zojwalla Naseem

CHIEF MEDICAL OFFICER

Officer
14,202 -10.9%
8.66
US$122,989 		14,202 -10.9% 8.66 US$122,989
2024-12-11 2024-12-10 S Sale
2.9
Harmon Cyrus
Non-Executive Director
8,256 -1.1%
9.37
US$77,359 		8,256 -1.1% 9.37 US$77,359
2024-12-11 2024-12-10 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
16,803 -2.9%
9.37
US$157,444 		16,803 -2.9% 9.37 US$157,444
Explore more

More insider trading research around Olema Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America